



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

Date: 18th July, 2015

To
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051

Sub: - Outcome of Board Meeting held on 18th July, 2015

Dear Sir

A meeting of the Board of Directors of the company was held on Saturday, the 18th day of July, 2015 at 11.00 A.M. at the Corporate Office of the Company at Indore. The Board *inter-alia* considered and approved the Un-audited Financial Results (both Standalone and Consolidated) of the company for the quarter ended 30th June, 2015, the Scheme of Arrangement and demerger of the company and decided to convene the 31st Annual General Meeting of the Company on Monday the 31st day of August, 2015 at 9.30 A.M. at the Classique Club, Behind Infinity Mall, Link Road, Oshiwara, Andheri (West), Mumbai-400 053.

Please find enclosed herewith Un-audited Financial Results (both Standalone and Consolidated) of the Company along with Limited Review Report by the auditors of the Company on the Un-audited financial results of the Company for the quarter ended 30th June, 2015.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

Thanking You

For Parenteral Drugs (India) Limited

Company Secretary

Encl.: a/a



PARENTERAL DRUGS (INDIA) LTD.



M5000712ID

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2015

PART -1					
Sr. No.	Particulars	3 Months Ended			(Rs In Lacs)
		June 2015	March 2015	June 2014	Year Ended
		Unaudited	Audited	Unaudited	March 2015
					Audited
	Income from Operation				
1	(a) Net Sales/Income from Operations (Net of Excise Duty)	5094.76	3614.56	5287.93	17589.31
	(b) Other Operating Income	92.57	64.35	2.84	69.68
	Total Income From Operation (Net)	5187.33	3678.91	5290.77	17658.99
2	Expenditure				
	a) Cost of Material Consumed	3120.41	1374.96	2815.89	8689.93
	b) Purchase of Stock In Trade				
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	(104.27)	(459.63)	194.50	(784.83)
	d) Employee Benefit Expenses	425.14	455.09	463.57	1844.36
	e) Depreciation and Amortisation Expenses	525.88	1058.70	442.12	2385.06
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	1218.48	1841.83	1619.53	6568.73
	Total Expenses	5185.64	4270.95	5535.61	18703.25
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1.69	(592.04)	(244.84)	(1044.26)
4	Other Income	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	1.69	(592.04)	(244.84)	(1044.26)
6	Finance costs	1438.76	1550.43	1421.03	5917.34
7	Profit after Interest but before Exceptional items (5-6)	(1437.07)	(2142.47)	(1665.87)	(6961.60)
8	Exceptional Items	0.00	(40.72)	0.00	(40.72)
9	Profit / (Loss) from ordinary activities before tax	(1437.07)	(2183.19)	(1665.87)	(7002.32)
10	Tax Expenses	6.01	(434.08)	91.89	(1593.84)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1443.08)	(1749.11)	(1757.76)	(5408.48)
12	Extraordinary items (net of tax expense) Lakhs)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1443.08)	(1749.11)	(1757.76)	(5408.48)
14	Share of profit / (loss) of associates*				
15	Minority interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1443.08)	(1749.11)	(1757.76)	(5408.48)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				6418.93
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(4.84)	(5.87)	(5.90)	(18.14)
	(b) Diluted	(4.84)	(5.87)	(5.90)	(18.14)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(4.84)	(5.87)	(5.90)	(18.14)
	(b) Diluted	(4.84)	(5.87)	(5.90)	(18.14)

Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA

Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

PART -II

A PARTICULARS OF SHAREHOLDING					
1	Public Shareholding				
	-No. of Shares	7,967,057	7,967,057	7,967,057	7,967,057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-No. of shares	21,849,243	21,849,243	15,076,441	21,849,243
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	69.00%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	73.28%	50.56%	73.28%
	b) Non-encumbered				
	-No. of shares	-	-	6,772,802	-
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	31.00%	-
	-Percentage of Shares (as a % of the total share capital of the Company)	-	-	22.72%	-
B	Detail of Investor Compliant	3 months ended (30.06.2015)			
	Pending at the beginning of the quarter	0			
	Received during the quarter	0			
	Disposed of during the quarter	0			
	Remaining unresolved at the end of the quarter	0			

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 18th July 2015.
- At the moment the Company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of Board of Directors

Vinod Kumar Gupta
Managing Director

Place: Indore
Date: 18th July 2015



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ



M5000712ID

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2015

PART - I		(Rs in Lacs)			
Sr. No.	Particulars	3 Months Ended		Year Ended	
		June 2015	March 2015	June 2014	March 2015
		Unaudited	Audited	Unaudited	Audited
1	Income from Operation				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	8804.81	6176.38	7711.28	26266.92
	(b) Other Operating Income	94.65	86.17	4.50	96.36
	Total Income From Operation (Net)	8899.46	6262.55	7715.78	26363.28
2	Expenditure				
	a) Cost of Material Consumed	4336.09	2580.37	4345.80	14936.95
	b) Purchase of Stock In Trade	859.40			
	c) Change in Inventories of Finished Goods, Work in Progress and Stock in trade	297.12	(675.05)	73.57	(2292.58)
	d) Employee Benefit Expenses	557.67	615.17	596.51	2358.09
	e) Depreciation and Amortisation Expenses	676.14	1373.41	574.90	3097.90
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	2059.95	3245.06	2429.18	9833.07
	Total Expenses	8786.37	7138.96	8019.96	27933.43
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	113.09	(876.41)	(304.18)	(1570.15)
4	Other Income	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	113.09	(876.41)	(304.18)	(1570.15)
6	Finance costs	1777.84	1898.58	1652.38	7025.16
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(1664.75)	(2774.99)	(1956.56)	(8595.31)
8	Exceptional items	0.00	40.72	0.00	40.72
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1664.75)	(2815.71)	(1956.56)	(8636.03)
10	Tax Expenses	58.09	(712.87)	91.89	(1872.63)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1722.84)	(2102.84)	(2048.45)	(6763.40)
12	Extraordinary items (net of tax expense Lakhs)				0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1722.84)	(2102.84)	(2048.45)	(6763.40)
14	Share of profit / (loss) of associates*				0.00
15	Minority interest *				
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1722.84)	(2102.84)	(2048.45)	(6763.40)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				8070.76
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.78)	(7.05)	(6.87)	(22.68)
	(b) Diluted	(5.78)	(7.05)	(6.87)	(22.68)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):				
	(a) Basic	(5.78)	(7.05)	(6.87)	(22.68)
	(b) Diluted	(5.78)	(7.05)	(6.87)	(22.68)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481



PARENTERAL DRUGS (INDIA) LTD.



JAS-ANZ
C
M5000712ID

PART -II

A PARTICULARS OF SHAREHOLDING					
1	Public Shareholding				
	-No. of Shares	7,967,057	7,967,057	7,967,057	7,967,057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%
2	Promoters and Promoter Group Shareholding **				
	a) Pledged/Encumbered				
	-No. of shares	21,849,243	21,849,243	15,076,441	21,849,243
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	69.00%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	73.28%	50.56%	73.28%
	b) Non-encumbered				
	-No. of shares	-	-	6,772,802	-
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	31.00%	-
	-Percentage of Shares (as a % of the total share capital of the Company)	-	-	22.72%	-
8	Detail of Investor Compliant	3 months ended (30.06.2015)			
	Pending at the beginning of the quarter	0			
	Received during the quarter	0			
	Disposed of during the quarter	0			
	Remaining unresolved at the end of the quarter	0			

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 18th July 2015
- The financial results of the subsidiary companies have been consolidated.
- At the moment the Company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
1	Income from operations & other income	5,187.33	3,678.91	5,290.77	17,658.99
2	Profit/Loss before tax	(1,437.07)	(2,183.19)	(1,665.87)	(7,002.32)
3	Profit/Loss after tax	(1,443.08)	(1,749.11)	(1,757.76)	(5,408.48)

For and on behalf of Board of Directors

Place: Indore
Date: 18th July 2015

Vinod Kumar Gupta
Managing Director

T.N. UNNI & Co.
Chartered Accountants

402, Alankar Point,
4-A, Rajgarh Kothi,
Geeta Bhawan Square,
A.B.Road,
Indore- 452001

Review Report to
National Stock Exchange of India Limited/
Bombay Stock Exchange Limited

We have reviewed the accompanying statement of unaudited financial results of M/s. Parenteral Drugs (India) Limited for the period ended 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Camp: Naduvannur, Dist. Kozhikode
Date : 18.07.2015

For T.N. UNNI & Co.
Chartered Accountants



T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C